Medsir

This study tests a drug called trastuzumab deruxtecan (T-DXd) against the usual treatment (a CDK4/6 inhibitor plus hormone therapy) for people with a certain type of advanced breast cancer. The cancer must be hormone receptor-positive, HER2-low or ultralow, and have a specific ge…

This study tests two drugs, camizestrant and ribociclib, together in people with advanced hormone receptor-positive (HR+) breast cancer. The goal is to see if the combination can delay cancer growth better than current treatments. About 150 adults who have already received hormon…

This phase 2 trial is testing whether giving the drug niraparib again after surgery can help women with ovarian cancer whose disease has come back in just a few spots. About 30 participants will take niraparib pills daily until their cancer grows or side effects become too much. …

This study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation) live longer without their cancer getting worse. About 240 adults whose cancer has stopped responding to standard hormone thera…

This study tests whether a blood test that looks for cancer DNA (ctDNA) can find breast cancer returning earlier than usual scans or exams. About 976 people with HR-positive/HER2-negative early breast cancer who had surgery will give blood samples over time. If the test shows sig…

This study tests a drug called repotrectinib in 20 people with a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. The main goal is to see if the drug can shrink or eliminate brain tumors. Participants will take the drug by mouth, and doctors will m…